Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab for psoriasis.

Alice B Gottlieb1

  • 1Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08901-0019, USA.

Journal of the American Academy of Dermatology
|August 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

Annals of the rheumatic diseases·2026
Same author

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy·2026
Same author

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

JAMA dermatology·2026
Same author

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-Q.

The Journal of clinical and aesthetic dermatology·2025
Same author

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.

Dermatology and therapy·2025
See all related articles

Infliximab effectively treats moderate to severe psoriasis, offering sustained clinical improvement for up to six months. This biologic therapy also normalizes skin cell activity and reduces inflammation, highlighting TNF-alpha

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic immune-mediated inflammatory disorder (IMID).
  • Current treatments have limitations in efficacy and duration.
  • Tumor Necrosis Factor-alpha (TNF-alpha) is implicated in psoriasis pathogenesis.

Purpose of the Study:

  • To review the efficacy and role of infliximab in treating psoriasis and other IMIDs.
  • To evaluate infliximab's impact on keratinocyte proliferation and epidermal inflammation.

Main Methods:

  • Review of existing literature on infliximab use in psoriasis.
  • Analysis of clinical response data from infliximab monotherapy trials.

Main Results:

  • Infliximab monotherapy demonstrates substantial and rapid response in moderate to severe psoriasis vulgaris.

Related Experiment Videos

  • Clinical improvement is maintained for up to 6 months in approximately 50% of patients without additional treatment.
  • Infliximab normalizes keratinocyte proliferation and differentiation, significantly reducing epidermal inflammation.

    • Conclusions:

    • Infliximab is a highly effective treatment for psoriasis, comparable to cyclosporine.
    • Sustained clinical benefits and normalization of skin pathology support infliximab's role.
    • These findings strongly support the clinical development of infliximab for psoriasis treatment and confirm TNF-alpha's pathogenic role.